
Insider and congress filings
Hims & Hers Health, Inc. (HIMS)
NYSE · Healthcare · 355 insider transactions · 2 congress trades · last filed 11 days ago
About Hims & Hers Health, Inc.
from the company's filings and listing, as of Oct 23, 2026- Exchange
- NYSE
- Sector
- Healthcare
- Industry
- Medical - Care Facilities
- Chief executive
- Andrew Dudum
- Employees
- 2,442
- Listed since
- -
- Market value
- $6.6B
- Price to earnings (12 mo)
- -
- Net income per share, as reported (12 mo)
- -$0.61
- Dividend yield
- -
Company news
1 article · newest first| Headline | Source | Date |
|---|---|---|
| Hims & Hers Health launches injectable and oral testosterone therapiesThe treatments are for eligible men with low testosterone and are offered with licensed providers through Hims. | Company release | Oct 21, 2026 |
Written by GetSignal with AI from the company's own SEC filings and press releases; each article links to its source. Not investment advice. Company news from every company we cover
Earnings
6 reported quarters · next on Nov 9, 2026| Quarter | EPS | EPS expected | Revenue | Revenue expected | Result |
|---|---|---|---|---|---|
| Q2 FY2026reported Aug 10, 2026 | -$0.37 | -$0.05 | $753.2M | $698.9M | EPS miss, GAAPRevenue beat |
| Q1 FY2026reported May 11, 2026 | -$0.40 | $0.03 | $608.1M | $616.8M | EPS miss, GAAPRevenue in line |
| Q4 FY2025reported Feb 23, 2026 | $0.07 | $0.02 | $617.8M | $619.2M | EPS beatRevenue in line |
| Q3 FY2025reported Nov 3, 2025 | $0.06 | $0.09 | $599.0M | $618.1M | EPS miss, GAAPRevenue miss |
| Q2 FY2025reported Aug 4, 2025 | $0.17 | $0.18 | $544.8M | $584.1M | EPS miss, GAAPRevenue miss |
| Q1 FY2025reported May 5, 2025 | $0.20 | $0.12 | $586.0M | $538.6M | EPS beat, GAAPRevenue beat |
Actual against the consensus estimate at the time. A flag marks a beat or a miss of more than 1.5% either way; inside that band the quarter is in line. A flag marked GAAP compares a GAAP figure the company reported with an adjusted consensus, two different measures, so a one-time gain or charge can move it either way. A flag reads n/a only when a number is missing. Quarterly EPS is the figure set against the consensus, usually adjusted, so the quarters need not add up to the 12-month net income per share above. An estimate is a forecast made by analysts, not a company target.
Executive pay
as filed for fiscal 2025 · proxy filed Apr 28, 2026| Executive | Salary | Stock awards | Other | Total |
|---|---|---|---|---|
| Mr. ElshenawyChief Technology Officer | $375K | $57.2M | $3.3M | $60.9M |
| Mr. DudumChief Executive Officer and Chairman | $495K | $10.6M | $11.8M | $23.0M |
| Mr. OkupeChief Financial Officer | $531K | $7.5M | $394K | $8.4M |
| Mr. ChiChief Operating Officer (previously Chief Commercial Officer) | $485K | $6.9M | $344K | $7.7M |
| Ms. BoughtonChief Legal Officer | $464K | $4.0M | $308K | $4.8M |
The summary compensation table from the proxy statement for fiscal 2025, with titles as filed then. 2 executives who have since left the company are named in that filing and not shown here. Read the filing
Institutional holders
13F positions as of Jun 30, 2026| Holder | Value | Shares | Shares vs prior qtr | % of shares out |
|---|---|---|---|---|
| BlackRock, Inc. | $995.2M | 28,703,514 | +9.0% | 12.39% |
| Vanguard Portfolio Management LLC | $366.1M | 10,559,314 | +3.7% | 4.56% |
| Vanguard Capital Management LLC | $330.8M | 9,541,384 | +2.2% | 4.12% |
| State Street Corp | $282.4M | 8,145,699 | +9.2% | 3.51% |
| Morgan Stanley | $248.0M | 7,152,498 | -19.5% | 3.09% |
| Divisadero Street Capital Management, LP | $208.3M | 6,009,505 | +1179.1% | 2.59% |
| Geode Capital Management, LLC | $197.0M | 5,681,832 | +9.3% | 2.45% |
| Goldman Sachs Group Inc | $179.4M | 5,173,865 | +110.8% | 2.23% |
| JPMorgan Chase & Co. | $159.5M | 4,766,781 | -9.0% | 2.06% |
| FMR LLC | $149.9M | 4,323,292 | +4535.2% | 1.87% |
| Marshall Wace, LLP | $146.2M | 4,217,767 | +482.4% | 1.82% |
| UBS Group AG | $92.3M | 2,660,810 | -35.9% | 1.15% |
A 13F reports long US equity positions and is filed within 45 days of the quarter end, so these are positions as they stood on Jun 30, 2026. For a manager's whole book see the fund directory. What a 13F covers and leaves out is explained in our guide to Form 13F.
Open-market insider trades
14 filings shown · newest filing first| Insider | Action | Shares | Price | Value | Trade date | Delay (business days) |
|---|---|---|---|---|---|---|
| Soleil BoughtonChief Legal Officer | Sold · scheduled | 3,461 | $29.06 | $101K | Oct 14, 2026filed Oct 15, 2026 | 1d |
| Soleil BoughtonChief Legal Officer | Sold · scheduled | 3,461 | $29.17 | $101K | Sep 30, 2026filed Oct 2, 2026 | 2d |
| Oluyemi OkupeChief Financial Officer | Sold · scheduled | 2,000 | $29.70 | $59K | Oct 1, 2026filed Oct 2, 2026 | 1d |
| Oluyemi OkupeChief Financial Officer | Sold · scheduled | 29,277 | $29.95 | $877K | Sep 22, 2026filed Sep 23, 2026 | 1d |
| Oluyemi OkupeChief Financial Officer | Sold · scheduled | 12,313 | $28.82 | $355K | Sep 17, 2026filed Sep 18, 2026 | 1d |
| Mohamed ElshenawyCTO | Sold · scheduled | 7,954 | $28.39 | $226K | Sep 15, 2026filed Sep 17, 2026 | 2d |
| Michael ChiChief Operating Officer | Sold · scheduled | 14,027 | $28.39 | $398K | Sep 15, 2026filed Sep 17, 2026 | 2d |
| Soleil BoughtonChief Legal Officer | Sold · scheduled | 6,236 | $27.86 | $174K | Sep 16, 2026filed Sep 17, 2026 | 1d |
| Soleil BoughtonChief Legal Officer | Sold · scheduled | 3,458 | $28.33 | $98K | Sep 2, 2026filed Sep 3, 2026 | 1d |
| Soleil BoughtonChief Legal Officer | Sold · scheduled | 25,111 | $27.55 | $692K | Aug 19, 2026filed Aug 20, 2026 | 1d |
| Oluyemi OkupeChief Financial Officer | Sold · scheduled | 4,938 | $29.99 | $148K | Aug 19, 2026filed Aug 20, 2026 | 1d |
| Deborah M. AutorChief Policy Officer | Sold · scheduled | 16,773 | $27.85 | $467K | Aug 18, 2026filed Aug 20, 2026 | 2d |
| Oluyemi OkupeChief Financial Officer | Sold · scheduled | 9,388 | $27.89 | $262K | Aug 17, 2026filed Aug 18, 2026 | 1d |
| Oluyemi OkupeChief Financial Officer | Sold · scheduled | 55,383 | $35.09 | $1.9M | Jun 18, 2026filed Aug 18, 2026 | 41d |
One row is one filing, newest filing first. A filing that reported its trade in several tranches is summed, priced at the weighted average, and marked with its line count. Scheduled: set up in advance under a Rule 10b5-1 trading plan. The delay counts business days from the trade to the filing, the unit of Form 4's two business day deadline: weekends and federal holidays are skipped. How the filing itself works is explained in our guide to Form 4.
Other Form 4 activity (20)
| Insider | Event | Shares | Date |
|---|---|---|---|
| Oluyemi OkupeChief Financial Officer | Option exercise | 14,000 | Sep 22, 2026 |
| Andrew DudumChief Executive Officer | Other (see filing) | 977,566 | Aug 27, 2026 |
| Andrew DudumChief Executive Officer | Gift | 463,289 | Aug 25, 2026 |
| Oluyemi OkupeChief Financial Officer | Option exercise | 4,938 | Aug 19, 2026 |
| Deborah M. AutorChief Policy Officer | Tax withholding | 16,147 | Aug 14, 2026 |
| Deborah M. AutorChief Policy Officer | Option exercise | 32,920 | Aug 14, 2026 |
| Oluyemi OkupeChief Financial Officer | Option exercise | 71,616 | Aug 14, 2026 |
| Oluyemi OkupeChief Financial Officer | Option exercise | 9,388 | Aug 17, 2026 |
| Oluyemi OkupeChief Financial Officer | Tax withholding | 36,437 | Aug 14, 2026 |
| Oluyemi OkupeChief Financial Officer | Option exercise | 71,616 | Aug 14, 2026 |
| Michael ChiChief Operating Officer | Option exercise | 86,265 | Aug 14, 2026 |
| Michael ChiChief Operating Officer | Tax withholding | 47,702 | Aug 14, 2026 |
| Michael ChiChief Operating Officer | Option exercise | 86,265 | Aug 14, 2026 |
| Andrew DudumChief Executive Officer | Option exercise | 154,993 | Aug 14, 2026 |
| Andrew DudumChief Executive Officer | Tax withholding | 78,859 | Aug 14, 2026 |
| Andrew DudumChief Executive Officer | Option exercise | 154,993 | Aug 14, 2026 |
| Patrick Harrison CarrollChief Medical Officer | Option exercise | 25,927 | Aug 14, 2026 |
| Patrick Harrison CarrollChief Medical Officer | Tax withholding | 10,201 | Aug 14, 2026 |
| Patrick Harrison CarrollChief Medical Officer | Option exercise | 26,187 | Aug 14, 2026 |
| Kare SchultzDirector | Option exercise | 6,623 | Aug 14, 2026 |
Awards, option exercises, shares withheld to cover tax and gifts all file on the same form as a purchase or a sale. None of them is a decision to trade, so they sit here rather than beside the ones that are.
Congress trades in HIMS
2 disclosures of 2 on record · median 37d of the 45 allowedSince the trade: the stock's move from the trade date to the latest close we hold (figures as of Oct 24, 2026), not the member's result. Not investment advice.
| Member | Type | Action | Amount disclosed | Stock since the trade | Trade date | Disclosed | Delay |
|---|---|---|---|---|---|---|---|
| Tony Wied | Stock | Purchase | $500,001 - $1,000,000 | +8.5%S&P 500 +10.2% · -1.7 pts vs S&P 500 | Feb 3, 2026 | Mar 9, 2026 | 34d |
| Lisa C. McClainSpouse | Stock | Purchase | $1,001 - $15,000 | -56.3%S&P 500 +20.4% · -76.7 pts vs S&P 500 | Aug 4, 2025 | Sep 12, 2025 | 39d |
Since the trade is an estimate, set beside the S&P 500 over the same window, with the gap between the two in percentage points. The filing carries a band, not a fill, and a sale keeps the stock's sign, so a positive figure after a sale means the stock kept rising after it. An option row carries the underlying stock's move. A row marked n/a is one we hold no figure for.
A delay above 45 days is the gap between the dates on the report; we mark a filing late only after checking it.
"Not captured" means the band or the transaction type on the original report is missing from our data.
"Dates conflict" marks a row whose disclosure is dated before its trade on the record we hold. Both dates are printed as filed, and no since-the-trade figure is computed from them.
Every Congress trade in HIMS, filterable by party, chamber, type and account.
Members of Congress reporting a position
1 member · estimate, as of Oct 22, 20261 member reports a position (estimated). The largest estimated position is in the $500,001 - $1,000,000 band.
| Member | Party, chamber | Estimated position | Share of their portfolio |
|---|---|---|---|
| Tony Wied | Republican · House | $500,001 - $1,000,000 | 3.6% |
Estimate, as of Oct 22, 2026. Each position is modelled from the member's disclosed transactions and annual filings: the midpoint of each disclosed band, moved with the stock's price since the trade. It is a rough estimate of a reported position, not a figure from a filing, which is why it is shown as a band. Share of portfolio sets that estimate against the member's whole estimated public-stock portfolio.
Questions
Are insiders buying or selling HIMS?
Across the 14 most recent open-market filings shown here, 0 were purchases and 14 were sales. 14 were scheduled in advance under a Rule 10b5-1 plan.
Which members of Congress have traded HIMS?
Tony Wied and Lisa C. McClain disclosed HIMS transactions in the filings shown here.
Which members of Congress hold HIMS?
1 member of Congress reports a position in HIMS in the estimate we hold as of Oct 22, 2026. The estimated position belongs to Tony Wied. The estimate is built from disclosed transactions and annual filings, so it is shown as a band rather than a figure from a filing.
How quickly are HIMS trades disclosed?
Insider filings on this page reached the public a median of 1 business day after the transaction (weekends and federal holidays skipped), against the two business days Form 4 allows. Congressional disclosures took a median of 37 days, against the 45 the STOCK Act allows.
How to read a Form 4
A DECISION THE INSIDER MADE
COMPENSATION PLUMBING
Congress rows disclose a value range rather than an exact amount, and the STOCK Act allows up to 45 days to report. Full sourcing and the limits of this data are on the methodology page. A filing is a record of a transaction, not a signal, and nothing here is investment advice.
Data as of Oct 26, 2026.
